This site is intended for Healthcare Professionals only.

Morningside appoints two senior executives

Date:

Share post:

Morningside Pharmaceuticals Ltd has appointed new chief operating officer (COO) and chief financial officer (CFO) who ipso facto become members of the company’s board and governance committees.

Monica Huang has been promoted into the role of COO, while Cliff Fung joins Morningside as the new CFO.

Huang joined the company 12 years ago as an administrator, progressing to general manager and then operations director in 2017.

Fung has over 25 years’ experience of working in senior finance roles within the pharmaceutical sector. Previous to joining Morningside, he was a finance director at Aesica Pharmaceuticals.

Commenting on the new appointments, Dr Nik Kotecha OBE, the chief executive of Morningside Pharmaceuticals, said: “I am very pleased to welcome both Cliff and Monica onto the board of directors.

“We are beginning an exciting new chapter at Morningside, where the skills, experience and expertise of both individuals will be critical to delivering our ambitious future plans.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Haleon to close Maidenhead manufacturing site affecting 435 jobs

Despite the closure, Haleon will retain its presence in the UK with corporate offices in Weybridge and London Haleon,...

UK pharmacies cut prices for weight-loss drugs Wegovy, Mounjaro amidst escalating competition

Obesity experts raise concern that retail marketing of weight-loss drugs could trivialise their side-effects   British pharmacies and slimming...

MHRA says many online pharmacies are ‘unregulated’,’ illegal’, or ‘fraudulent’

MHRA's latest initiative aims to empower consumers in the fight against online pharmacy frauds The Medicines and Healthcare products...

MHRA outlines strategic approach to AI regulation in healthcare for patient safety

MHRA's strategic principles aim to foster innovation while upholding rigorous standards of patient safety and regulatory integrity In a...